Cerebrospinal Fluid Particles in Alzheimer Disease and Parkinson Disease

被引:30
|
作者
Yang, Yue [1 ]
Keene, C. Dirk [1 ]
Peskind, Elaine R. [2 ,3 ]
Galasko, Douglas R. [4 ]
Hu, Shu-Ching [5 ]
Cudaback, Eiron [1 ]
Wilson, Angela M. [1 ]
Li, Ge [2 ]
Yu, Chang-En [6 ,7 ]
Montine, Kathleen S. [1 ]
Zhang, Jing [1 ]
Baird, Geoffrey S. [1 ,8 ]
Hyman, Bradley T. [9 ]
Montine, Thomas J. [1 ]
机构
[1] Univ Washington, Dept Pathol, Seattle, WA 98195 USA
[2] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA
[3] VA Puget Sound Hlth Care Syst, VA Northwest Network Mental Illness Res Educ & Cl, Seattle, WA USA
[4] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA
[5] Univ Washington, Dept Neurol, Seattle, WA 98195 USA
[6] Univ Washington, Dept Med, Seattle, WA 98195 USA
[7] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA
[8] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA
[9] Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp, Boston, MA 02115 USA
关键词
Alzheimer disease; Biomarkers; Cerebrospinal fluid; Cognitive impairment; Neurodegenerative disease; Parkinson disease; APOLIPOPROTEIN-A-I; AMYLOID PRECURSOR PROTEIN; MILD COGNITIVE IMPAIRMENT; GENOME-WIDE ASSOCIATION; CENTRAL-NERVOUS-SYSTEM; E APOE POLYMORPHISM; TARGETED REPLACEMENT; MEMBRANE-VESICLES; MOUSE MODEL; CIRCULATING MICROPARTICLES;
D O I
10.1097/NEN.0000000000000207
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Human cerebrospinal fluid (CSF) contains diverse lipid particles, including lipoproteins that are distinct from their plasma counterparts and contain apolipoprotein (apo) E isoforms, apoJ, and apoAI, and extracellular vesicles, which can be detected by annexin V binding. The aim of this study was to develop a method to quantify CSF particles and evaluate their relationship to aging and neurodegenerative diseases. We used a flow cytometric assay to detect annexin V-, apoE-, apoAI-, apoJ-, and amyloid (A) (42)-positive particles in CSF from 131 research volunteers who were neurologically normal or had mild cognitive impairment (MCI), Alzheimer disease (AD) dementia, or Parkinson disease. APOE epsilon 4/epsilon 4 participants had CSF apoE-positive particles that were more frequently larger but at an 88% lower level versus those in APOE epsilon 3/epsilon 3 or APOE epsilon 3/epsilon 4 patients; this finding was reproduced in conditioned medium from mouse primary glial cell cultures with targeted replacement of apoE. Cerebrospinal fluid apoE-positive and -amyloid (A(42))-positive particle concentrations were persistently reduced one-third to one-half in middle and older age subjects; apoAI-positive particle concentration progressively increased approximately 2-fold with age. Both apoAI-positive and annexin V-positive CSF particle levels were reduced one-third to one-half in CSF of MCI and/or AD dementia patients versus age-matched controls. Our approach provides new methods to investigate CNS lipid biology in relation to neurodegeneration and perhaps develop new biomarkers for diagnosis or treatment monitoring.
引用
收藏
页码:672 / 687
页数:16
相关论文
共 50 条
  • [31] Cerebrospinal fluid markers of neurodegeneration in Parkinson's disease
    Vranova, H.
    Nevrly, M.
    Mares, J.
    Kanovsky, P.
    Stejskal, D.
    MOVEMENT DISORDERS, 2009, 24 : S285 - S286
  • [32] Metabolomic investigations in cerebrospinal fluid of Parkinson's disease
    Willkommen, Desiree
    Lucio, Marianna
    Moritz, Franco
    Forcisi, Sara
    Kanawati, Basem
    Smirnov, Kirill S.
    Schroeter, Michael
    Sigaroudi, Ali
    Schmitt-Kopplin, Philippe
    Michalke, Bernhard
    PLOS ONE, 2018, 13 (12):
  • [33] Cerebrospinal fluid biomarker for Parkinson's disease: An overview
    Maass, Fabian
    Schulz, Isabel
    Lingor, Paul
    Mollenhauer, Brit
    Baehr, Mathias
    MOLECULAR AND CELLULAR NEUROSCIENCE, 2019, 97 : 60 - 66
  • [34] Cerebrospinal fluid lipidomics for biomarkers of Alzheimer's disease†
    Byeon, Seul Kee
    Madugundu, Anil K.
    Jain, Ankit P.
    Bhat, Firdous A.
    Jung, Jae Hun
    Renuse, Santosh
    Darrow, Jacqueline
    Bakker, Arnold
    Albert, Marilyn
    Moghekar, Abhay
    Pandey, Akhilesh
    MOLECULAR OMICS, 2021, 17 (03) : 454 - 463
  • [35] Association of cerebrospinal fluid Neurogranin with Alzheimer’s disease
    Lijun Wang
    Aging Clinical and Experimental Research, 2019, 31 : 185 - 191
  • [36] Cerebrospinal fluid biomarkers in Alzheimer disease a fractional improvement?
    Galasko, D
    ARCHIVES OF NEUROLOGY, 2003, 60 (09) : 1195 - 1196
  • [37] Cerebrospinal fluid microRNA profile in Alzheimer's disease
    Denk, J.
    Arlt, S.
    Boelmans, K.
    Jahn, H.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2014, 24 : S636 - S636
  • [38] Cerebrospinal fluid proteomic biomarkers for Alzheimer's disease
    Finehout, Erin J.
    Franck, Zsofia
    Choe, Leila H.
    Relkin, Norman
    Lee, Kelvin H.
    ANNALS OF NEUROLOGY, 2007, 61 (02) : 120 - 129
  • [39] Trace elements in the cerebrospinal fluid in Alzheimer's disease
    Rao, KSJ
    Shanmugavelu, P
    Shankar, SK
    Devi, RPR
    Rao, RV
    Pande, S
    Menon, RB
    ALZHEIMERS REPORTS, 1999, 2 (06): : 333 - 338
  • [40] Analysis of the Cerebrospinal Fluid Proteome in Alzheimer's Disease
    Khoonsari, Payam Emami
    Haggmark, Anna
    Lonnberg, Maria
    Mikus, Maria
    Kilander, Lena
    Lannfelt, Lars
    Bergquist, Jonas
    Ingelsson, Martin
    Nilsson, Peter
    Kultima, Kim
    Shevchenko, Ganna
    PLOS ONE, 2016, 11 (03):